Rho-Kinase Inhibition Assay

This bioassay, conducted by Natural Remedies Pvt. Ltd. Bioassay Research Laboratory, identifies and quantifies a well-established physiological mechanism through which VigRX may support erectile function: inhibition of Rho-kinase II, an enzyme that plays a critical role in maintaining penile smooth muscle contraction and limiting blood flow to the penis. Understanding this mechanism provides a scientific rationale for VigRX's observed benefits that is entirely distinct from — and complementary to — the pathway targeted by pharmaceutical ED drugs.

Background — The Rho-Kinase Pathway

Penile erection depends on relaxation of cavernous smooth muscle and increased blood flow into erectile tissue. Rho-kinase is a key regulator of smooth muscle tone: it phosphorylates and inactivates myosin phosphatase (MP), which in turn keeps smooth muscle contracted and the penis in a flaccid (detumescent) state. Inhibiting Rho-kinase allows MP to become active, dephosphorylates myosin, reduces smooth muscle tone, and enables penile erection. Crucially, this mechanism operates independently of the nitric oxide/cGMP/PDE-5 pathway that drugs like Sildenafil target — meaning Rho-kinase inhibition may provide benefit even when PDE-5 pathways are impaired.

Study Design

VigRX tablet blend (Lot #120657) was prepared by sonicating 2,000 mg in methanol and making up to 100 mL with ultra-pure water. The filtrate was used for the assay. Using the Cyclex Rho-Kinase Assay Kit (CY-1160, Japan) — a validated ELISA-based platform — VigRX was tested at concentrations from 125 to 2,000 µg/mL against Rho-kinase II enzyme. The known Rho-kinase specific inhibitor Y-27632 was used as the positive control. Percent inhibition was calculated for each concentration, and IC50 was determined using log-probit analysis.

Results

VigRX demonstrated dose-dependent inhibition of Rho-kinase II activity across the concentration range tested. At 500 µg/mL, VigRX inhibited Rho-kinase by approximately 28.6%. The calculated IC50 was 965 µg/mL (95% CI: 796–1,217 µg/mL). For reference, the pharmaceutical positive control Y-27632 achieved an IC50 of 0.199 µg/mL. A parallel independent assay conducted by AIBMR Life Sciences using the same kit reported a consistent IC50 of 1,673 µg/mL (95% CI: 1,216–2,710 µg/mL), corroborating the findings across independent laboratory settings.

Significance

The identification of Rho-kinase inhibition as a mechanism of action for VigRX is scientifically meaningful for several reasons. First, it provides a biologically plausible explanation for the intracavernous pressure increases and improved erectile function observed in animal studies. Second, because this pathway is independent of PDE-5 inhibition, VigRX is unlikely to produce the cardiovascular interaction risks associated with pharmaceutical ED drugs — making it suitable for a broader range of users. Third, the dose-dependent nature of the inhibition is consistent with a genuine pharmacological effect rather than a nonspecific result.

Conclusion

VigRX tablet blend exhibits measurable, dose-dependent Rho-kinase II inhibitory activity, providing a clear and credible scientific mechanism for its observed benefits in supporting male erectile function. This assay, conducted under validated laboratory conditions and corroborated by an independent parallel study, positions VigRX as a herbal formula with a real and well-understood mechanism of action — not merely empirical tradition — supporting its use in male sexual wellness.

Click here to read the full report →
Explore the complete VigRX product line →